# A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

> **NCT05276076** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ViGenCell Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** VM-001 1X10^6 cells/kg
- **BIOLOGICAL:** VM-001 3X10^6 cells/kg
- **BIOLOGICAL:** VM-001 5X10^6 cells/kg
- **BIOLOGICAL:** VM-001 1X10^6 cells/kg two dose
- **BIOLOGICAL:** VM-001 1X10^6 cells/kg four dose

## Key facts

- **NCT ID:** NCT05276076
- **Lead sponsor:** ViGenCell Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-20
- **Primary completion:** 2024-11-20
- **Final completion:** 2025-11-20
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276076, "A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05276076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*